- Global Pharma News & Resources

Xerostomia Therapeutics Market Business Growth Statistics, Drivers and Key Players Insights | Acacia Pharma Group PLC, Colgate-Palmolive, Church & Dwight Co. Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC

Pune, Maharashtra, India, June 24 2020 (Wiredrelease) Data Bridge Market Research — Xerostomia Therapeutics Market report covers many business strategies such as new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to amplify their footprints in the market. This global market report additionally encompasses predictions utilizing a practical arrangement of suspicions and techniques. Depending on client’s demand, huge amount of business, product and market related information has been brought together via this report that eventually helps businesses create better strategies. Xerostomia Therapeutics Market is the finest market research report which is the result of proficient team and their potential capabilities.

Xerostomia Therapeutics Market is expected to rise from its initial estimated value of USD 648.94 billion in 2018 to an estimated value of USD 874.55 billion by 2026 registering a CAGR of 3.8% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising geriatric population over the world and prevalence of demand of arthroscopy in these populations.

Click to Get Global Xerostomia Therapeutics Market Research Sample PDF Copy Here @

Major market competitors currently working in the xerostomia therapeutics market are:

Acacia Pharma Group PLC,


Church & Dwight Co. Inc.,

GlaxoSmithKline PLC,

Hikma Pharmaceuticals PLC,



Parnell Pharmaceuticals Inc.,


Pfizer Inc.,

Sun Pharmaceutical Industries Ltd,

Synedgen Inc.

Key Developments in the Xerostomia Therapeutics Market:

In October 2018, Synedgen Incand the subsidiary Prisyna, announced the launch of Moisyn for the treatment of xerostomia dry mouth.

May 2018, Synedgen Inc. and the subsidiary Prisyna , received 510(k) clearance from the US Food and Drug Administration (FDA) to market its family of Moisyn products designed to treat xerostomia.  The clearance of the drug from FDA will help the company to provide the Moisyn products to the patients for the treatment and can alleviate the dry mouth symptoms.

Xerostomia is a disease leading to oral dryness and are not easily diagnosed. Dryness of mouth is associated with the altered salivary gland functionality and other etiologies causing oral issues. Xerostomia caused due to the absence of saliva flow, and this is due to shrinkage of salivary gland. The xerostomia therapeutics helps to treat these symptoms associated with the dry mouth. The dry mouth symptoms impacts the life style quality of the patient and causes difficulty in the swallowing, chewing and speaking which can lead to the thick oral mucus, sleep disturbance and bad breathing.

Table of Content: Xerostomia Therapeutics Market

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Xerostomia Therapeutics Market Landscape

Part 04: Xerostomia Therapeutics Market Sizing

Part 05: Xerostomia Therapeutics Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

And More…..Get Detailed TOC @

Xerostomia Therapeutics Market : Segmentation

Xerostomia Therapeutics Market : By Type

Salivary Stimulants,

Salivary Substitutes,


Xerostomia Therapeutics Market : By Prescription based



Xerostomia Therapeutics Market : By Geography

North America,

South America,



Middle East and Africa

Xerostomia Therapeutics Market :Competitive Analysis

The global xerostomia therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of xerostomia therapeutics market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key focus of the report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining market growth

It provides five-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Purchase this report, List of Tables & Figures and in-depth Table of Contents on “Global Xerostomia Therapeutics Market” Report 2019 @

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


This content has been published by Data Bridge Market Research company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 24-Jun-2020